Carisma Therapeutics

Focus: Carisma Therapeutics is a Philadelphia-based biotechnology company focused on CAR macrophage immunotherapy for rare diseases. The company is in early-stage clinical development with a highly specialized therapeutic approach.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Carisma Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Carisma Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CT-0508

HER2-positive

PHASE_1

Clinical Trials (1)

NCT04660929CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Phase 1

Help build intelligence for Carisma Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer a novel modality: CAR macrophage therapy is an emerging immunotherapy platform with limited competition and significant intellectual property potential.
Rare disease focus offers accelerated pathways and smaller, more focused clinical teams for hands-on involvement.
Philadelphia biotech hub location provides access to academic partnerships and regional talent network.

Watch Out For

Early-stage pipeline with only 2 Phase 1 programs and no marketed products limits revenue visibility and long-term job stability.
No current hiring activity (0 open positions) suggests resource constraints or development stage not yet requiring expansion.
Missing financial data (funding, cash position, revenue) indicates private status with undisclosed capital runway and exit timeline uncertainty.

Generated by Claude from Carisma Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CT-0525

HER2-positive

PHASE_1

Clinical Trials (1)

NCT06254807CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles